Post Blogs, Photos, Youtube, Vimeo Videos, Topics, Events, Groups.
+ Larger Font | - Smaller Font

Welcome to Robins Social Network

Be part of the community and join us today!

About 75 drug candidates based on synlet gene pairs are being evaluated for the treatment of various types of cancers; presently, there are over 20 screening platforms enabling therapy development efforts

Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment


To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this link


The USD 8 billion (by 2030) financial opportunity within the synthetic lethality-based drugs and targets market has been analyzed across the following segments:

§  Type of molecule

§  Small Molecule

§  Biologic


§  Target disease indication

§  Breast Cancer

§  Colorectal Cancer

§  Fallopian Tube Cancer

§  Gastric Cancer

§  Head and Neck Cancer

§  Lung Cancer

§  Ovarian Cancer

§  Peritoneal Cancer

§  Others


§  Type of synlet target

§  APE1 / Ref-1

§  Chk1

§  GLS1


§  Pol θ

§  PP2A

§  Wee1


§  Route of administration 

§  Oral

§  Intravenous


§  Key geographical regions

§  North America

§  Europe

§  Asia Pacific

  • Rest of the World


The, report features the following companies, which we identified to be key players in this domain:

§  AbbVie

§  AstraZeneca

§  AtlasMedx

§  BeiGene

§  Chordia Therapeutics

§  Clovis Oncology

§  GlaxoSmithKline

§  IDEAYA Biosciences

§  Mission Therapeutics

§  Pfizer

§  Repare Therapeutics

§  Sierra Oncology

§  SyntheX Labs


Table of Contents


1. Preface

2. Executive Summary

3. Introduction to DNA Damage and Repair Systems

4. Introduction to Synthetic Lethality

5. Market Overview

6. Company Profiles

7. Emerging Trends on Social Media 

8. Publication Analysis

9. Abstract Analysis

10. Academic Grants Analysis

11. Funding and Investment Analysis

12. Target Benchmark Analysis


13. Role of Companion Diagnostics in Synthetic Lethality


14. Market Forecast

15. Concluding Remarks

16. Executive Insights


17. Appendix 1: Tabulated Data


18. Appendix 2: List of Companies and Organizations



To purchase a copy, please visit


Contact Details

Gaurav Chaudhary

+1 (415) 800 3415 

on January 5 at 9:01

Comments (0)

Become a member and experience a unique opportunity to post blogs, photos, Youtube Vimeo videos, topics, events, and create groups on Robin's Social Networking Site. Use Robin's Social to sell products, services and market your business when posting blogs.

By registering and posting content, you agree to the terms listed at... Posting Terms and Conditions. Enjoy!

© 2022 Content By Members. All Rights Reserved.